(Stroke. 1999;30:180-182.)
© 1999 American Heart Association, Inc.
Comments, Opinions, and Reviews |
Neuroprotection for Acute Stroke
Making Clinical Trials Work
From the Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, Scotland.
Correspondence to Keith W. Muir, MD, MRCP, Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow G51 4TF, Scotland. E-mail k.muir{at}clinmed.gla.ac.uk
Background—With the exception of the National Institutes of Neurological Disorders and Stroke trial of recombinant tissue plasminogen activator, clinical trials in stroke have failed to show improved outcome. If further negative results such as those of recent large neuroprotective trials are to be avoided, trial methodology must be reevaluated.
Summary—Because there is little evidence from animal focal ischemia models for protection of white matter, glia, or subcortical neurons, the logical target population for initial clinical trials is patients with middle cerebral artery stroke involving cerebral cortex. Clinical differentiation of moderate to large middle cerebral stroke from lacunar stroke is possible with the Oxfordshire Community Stroke Project classification but less readily achieved by numerical stroke scales. Several imaging techniques can further distinguish middle cerebral stroke patients with a "penumbra" potentially amenable to intervention from those without a penumbra, in whom outcome appears already determined. The window for intervention may be better defined by imaging than by time alone. Shortened follow-up periods may reduce variation in outcome attributable to differences in provision of rehabilitation or secondary preventative treatments among centers, and imaging may provide useful surrogate end points.
Conclusions—Clinical trials restricted to patients with large middle cerebral stroke accompanied by radiological evidence of a penumbra should be an essential component of drug development. Slower recruitment may be offset by extended time windows and requirements for fewer patients. Imaging may define surrogate evidence of biological effect prior to embarking on a phase 3 program.
Key Words: clinical trials • lacunar infarction • magnetic resonance imaging • neuroprotection • tomography, emission computed
This article has been cited by other articles:
 |
|
 |
|
  A.A. Konstas, G.V. Goldmakher, T.-Y. Lee, and M.H. Lev Theoretic Basis and Technical Implementations of CT Perfusion in Acute Ischemic Stroke, Part 2: Technical Implementations AJNR Am. J. Neuroradiol., May 1, 2009; 30(5): 885 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Aslanyan, C. J. Weir, K. W. Muir, K. R. Lees, and for the IMAGES Study Investigators Magnesium for Treatment of Acute Lacunar Stroke Syndromes: Further Analysis of the IMAGES Trial Stroke, April 1, 2007; 38(4): 1269 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Arakawa, P. M. Wright, M. Koga, T. G. Phan, D. C. Reutens, I. Lim, M. R. Gunawan, H. Ma, N. Perera, J. Ly, et al. Ischemic Thresholds for Gray and White Matter: A Diffusion and Perfusion Magnetic Resonance Study Stroke, May 1, 2006; 37(5): 1211 - 1216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kassner, T. Roberts, K. Taylor, F. Silver, and D. Mikulis Prediction of Hemorrhage in Acute Ischemic Stroke Using Permeability MR Imaging AJNR Am. J. Neuroradiol., October 1, 2005; 26(9): 2213 - 2217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lyden, L. Claesson, S. Havstad, T. Ashwood, and M. Lu Factor Analysis of the National Institutes of Health Stroke Scale in Patients With Large Strokes Arch Neurol, November 1, 2004; 61(11): 1677 - 1680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Fiehler, T. Kucinski, K. Knudsen, M. Rosenkranz, G. Thomalla, C. Weiller, J. Rother, and H. Zeumer Are There Time-Dependent Differences in Diffusion and Perfusion Within the First 6 Hours After Stroke Onset? Stroke, September 1, 2004; 35(9): 2099 - 2104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Lapchak and J. A. Zivin Ebselen, a Seleno-Organic Antioxidant, Is Neuroprotective After Embolic Strokes in Rabbits: Synergism With Low-Dose Tissue Plasminogen Activator Stroke, August 1, 2003; 34(8): 2013 - 2018. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D M Brown and S R Levine Clinical radiologic correlations in acute stroke: is the signal intensity at the end of the tunnel getting brighter quicker? J. Neurol. Neurosurg. Psychiatry, July 1, 2003; 74(7): 840 - 841. [Full Text] [PDF]
|
|
|
|
|
|
S J Allder, A R Moody, A L Martel, P S Morgan, G S Delay, J R Gladman, and G G Lennox Differences in the diagnostic accuracy of acute stroke clinical subtypes defined by multimodal magnetic resonance imaging J. Neurol. Neurosurg. Psychiatry, July 1, 2003; 74(7): 886 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Adams Jr, R. J. Adams, T. Brott, G. J. del Zoppo, A. Furlan, L. B. Goldstein, R. L. Grubb, R. Higashida, C. Kidwell, T. G. Kwiatkowski, et al. Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association Stroke, April 1, 2003; 34(4): 1056 - 1083. [Full Text] [PDF]
|
|
|
|
 |
|
 K W Muir Magnesium in stroke treatment Postgrad. Med. J., November 1, 2002; 78(925): 641 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Gladstone, S. E. Black, and A. M. Hakim Toward Wisdom From Failure: Lessons From Neuroprotective Stroke Trials and New Therapeutic Directions Stroke, August 1, 2002; 33(8): 2123 - 2136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Muir Heterogeneity of Stroke Pathophysiology and Neuroprotective Clinical Trial Design Stroke, June 1, 2002; 33(6): 1545 - 1550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Williams, X. M. Lu, B. Slusher, and F. C. Tortella Electroencephalogram Analysis and Neuroprotective Profile of the N-Acetylated-alpha -Linked Acidic Dipeptidase Inhibitor, GPI5232, in Normal and Brain-Injured Rats J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 48 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Helpern The Missing Element AJNR Am. J. Neuroradiol., August 1, 2001; 22(7): 1235 - 1236. [Full Text] [PDF]
|
|
|
|
|
|
J. Serena, R. Leira, J. Castillo, J. M. Pumar, M. Castellanos, and A. Davalos Neurological Deterioration in Acute Lacunar Infarctions : The Role of Excitatory and Inhibitory Neurotransmitters Stroke, May 1, 2001; 32(5): 1154 - 1161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Samsa and D. B. Matchar Have Randomized Controlled Trials of Neuroprotective Drugs Been Underpowered? : An Illustration of Three Statistical Principles Stroke, March 1, 2001; 32(3): 669 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. B. Marshall, K. J. Duffin, A. R. Green, R. M. Ridley, and S. P. Finklestein NXY-059, a Free Radical-Trapping Agent, Substantially Lessens the Functional Disability Resulting From Cerebral Ischemia in a Primate Species Editorial Comment Stroke, January 1, 2001; 32(1): 190 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. O. Karonen, Y. Liu, R. L. Vanninen, L. Østergaard, P. L. Kaarina Partanen, P. A. Vainio, E. J. Vanninen, J. Nuutinen, R. Roivainen, S. Soimakallio, et al. Combined Perfusion- and Diffusion-weighted MR Imaging in Acute Ischemic Stroke during the 1st Week: A Longitudinal Study Radiology, December 1, 2000; 217(3): 886 - 894. [Abstract] [Full Text]
|
|
|
|
|
|
V. N. Thijs, M. G. Lansberg, C. Beaulieu, M. P. Marks, M. E. Moseley, and G. W. Albers Is Early Ischemic Lesion Volume on Diffusion-Weighted Imaging an Independent Predictor of Stroke Outcome? : A Multivariable Analysis Stroke, November 1, 2000; 31(11): 2597 - 2602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Williams, J. R. Dave, J. B. Phillips, Y. Lin, R. T. McCabe, and F. C. Tortella Neuroprotective Efficacy and Therapeutic Window of the High-Affinity N-Methyl-D-aspartate Antagonist Conantokin-G: In Vitro (Primary Cerebellar Neurons) and In Vivo (Rat Model of Transient Focal Brain Ischemia) Studies J. Pharmacol. Exp. Ther., July 1, 2000; 294(1): 378 - 386. [Abstract] [Full Text]
|
|
|
|
|
|
G. Seidel, C. Algermissen, A. Christoph, T. Katzer, M. Kaps, and R. W. Baumgartner Visualization of Brain Perfusion With Harmonic Gray Scale and Power Doppler Technology : An Animal Pilot Study Editorial Comment: An Animal Pilot Study Stroke, July 1, 2000; 31(7): 1728 - 1734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Furlan CVA: Reducing the Risk of a Confused Vascular Analysis : The Feinberg Lecture Stroke, June 1, 2000; 31(6): 1451 - 1456. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Furlan, R. Higashida, L. Wechsler, M. Gent, H. Rowley, C. Kase, M. Pessin, A. Ahuja, F. Callahan, W. M. Clark, et al. Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial JAMA, December 1, 1999; 282(21): 2003 - 2011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Weinreb and L. A. Levin Is Neuroprotection a Viable Therapy for Glaucoma? Arch Ophthalmol, November 1, 1999; 117(11): 1540 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.E. Baird, S. Warach, K. W. Muir, and D. G. Grosset Using Pathophysiology in Acute Stroke Trials Response Stroke, June 1, 1999; 30(6): 1293 - 1293. [Full Text] [PDF]
|
|